Thank you for tuning into our EBN Web Seminar

When younger people get cancer, the biology is often fundamentally different and the implications for treatment are significant. This is a trend that doesn't get enough attention and understanding it matters for patients, families, and the clinicians caring for them.

In this clip, Dr. Yousuf Zafar, Chief Medical Officer at AccessHope, explains why cancers diagnosed in younger patients tend to be more biologically aggressive, are more frequently caught at a later stage, and in some cases respond differently to treatment.

In 2025 alone, more than 50 new cancer drugs, indications, and biosimilars were approved — and that's on top of everything that came before. In this clip, Dr. Yousuf Zafar, Chief Medical Officer at AccessHope, explains why that pace of innovation is nearly impossible for community oncologists to track, and what it means for patients who may not be receiving the most advanced or evidence-based treatment available today.

Only 35% of cancer patients are currently receiving appropriate genomic testing — and the consequences are significant. Without the right test, it's impossible to identify the right targeted treatment for a patient's cancer.

In this clip, experts explore the diagnostics gap in oncology: why it exists, what it costs patients, and how access to comprehensive genomic testing can change treatment outcomes.

Only 60% of cancer treatment in the US follows established guidelines — and the best outcomes are concentrated at NCI-Designated Comprehensive Cancer Centers that 80% of patients never access.

In this clip, Dr. Yousuf Zafar, Chief Medical Officer at AccessHope, breaks down the care equity divide and what it means for patients being treated in the community.